+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 18 Actively Recruiting clinical trials

E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the safety and immune response of an investigational yellow fever vaccine called vYF in young children aged 9 months to 5 years. This Phase III study compares vYF with two licensed yellow fever vaccines, Stamaril and YF-VAX, including when vYF is given alongside the measles, mumps, and rubella MMR vaccine in infants aged 11 to 15 months. The study aims to see if vYF can safely help the body develop protective antibodies against yellow fever. Participants will be randomized into groups by age to receive one dose of either vYF, Stamaril, or YF-VAX vaccine. A special group of infants aged 11 to 15 months will receive vYF together with the MMR vaccine in one visit. A subset of children aged 9 to 24 months will be invited to receive a booster dose of the yellow fever vaccine three years after the initial vaccination. The booster is not offered to the group receiving the combined vYF and MMR vaccine. Participants will be involved for about three years, with some in the booster group followed for an additional six months. The study includes multiple blood tests to measure immune response at several time points, starting from the day of vaccination and continuing annually up to three years. Safety is monitored closely through reports of side effects and laboratory tests. The main outcome is the percentage of participants developing antibodies against yellow fever 28 days after vaccination.

Age: 9Months - 5YearsAll GendersPhase 3
15 locations
P

Actively Recruiting

Healthy Volunteer

This research aims to evaluate the immune response and safety of an investigational chickenpox vaccine VNS Vaccine compared to an already approved vaccine called Varivax VV. The study focuses on healthy children who have not previously had chickenpox or received a chickenpox vaccine, and takes place when the second dose is given three months after the first dose, which is administered between 12 and 15 months of age. Participants are randomly assigned to one of three groups one group receives two doses of the Varivax vaccine another group receives two doses of the investigational VNS vaccine and the third group receives a first dose of Varivax followed by a second dose of the VNS vaccine. Additional vaccines including measles, mumps, and rubella MMR, hepatitis A HAV, and pneumococcal conjugate vaccine PCV are given on the first day. In some countries, a second dose of MMR is also given between 15 and 18 months according to national guidelines. During the study, researchers will monitor immune responses by measuring specific antibodies against the chickenpox virus after the second dose, particularly 43 days post-vaccination. They will also track any local or systemic side effects following each vaccine dose, recording adverse events up to nearly nine months after the first dose. The total participation includes multiple visits over this time, ensuring detailed safety and immune response assessment for each child.

Age: 12Months - 15MonthsAll GendersPhase 3
6 locations
C

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the pain relief effects and obstetric outcomes of tramadol, paracetamol, and placebo in first-time pregnant women during active labor. This randomized, double-blind, placebo-controlled trial aims to compare how these treatments affect the duration of active labor and other important birth-related factors. The study focuses on nulliparous women and examines both maternal and newborn safety during labor and delivery. Participants receive a single intravenous dose of either tramadol 100 mg, paracetamol 1 g, or a saline placebo at the start of active labor, defined as cervical dilation of at least 4 cm with regular contractions. The study is carefully designed to keep patients and care providers unaware of the assigned treatment to ensure unbiased results. The treatments are administered by trained medical personnel following strict protocols. During the study, researchers collect data on labor duration, delivery type, use of oxytocin, and any side effects experienced by the mother or newborn. Pain levels are also measured before and after treatment. Safety monitoring continues up to 48 hours after birth. The trial includes regular assessments of labor progress and newborn health, with a total participation period covering labor through immediate postpartum. The study is funded and overseen by Universidad Nacional Autnoma de Honduras and conducted at Hospital Escuela in Tegucigalpa.

Age: 15Years - 45YearsFEMALEPhase 4
2 locations
R

Actively Recruiting

Researchers are evaluating two different management protocols for children aged 1 to 12 years with severe traumatic brain injury sTBI in Latin America. The study aims to determine if using a treatment approach guided by invasive intracranial pressure ICP monitoring leads to better outcomes compared to a protocol based solely on imaging and clinical exams. This trial builds on previous adult studies and addresses the unique needs of pediatric patients to improve care and guide global clinical practice. The study randomly assigns children to one of two treatment groups. One group receives care following a protocol that uses invasive ICP monitoring to guide management decisions, based on recommendations from the Brain Trauma Foundation Guidelines. The other group follows the CREVICE protocol, which manages sTBI using imaging and clinical examination without ICP monitoring. Both protocols focus on aggressive management of sTBI. The trial is conducted in eight pediatric intensive care units in Latin America, aiming to strengthen research skills among local pediatric intensivists. Participants will be closely monitored during their hospital stay, with the study measuring outcomes such as quality of life using the Pediatric Quality of Life Inventory PedsQL at three and six months, functional recovery with the Glasgow Outcome Scale - Extended Pediatric GOS-E Peds, mortality rates, brain-specific treatments, and length of stay in intensive care. Data will be collected for up to six months after injury to assess the effects of the two management strategies on recovery and complications.

Age: 1Year - 12YearsAll GendersPhase Not Applicable
11 locations
I

Actively Recruiting

Cancer is a major cause of illness and death among children, adolescents, and young adults CAYAs, particularly in low- and middle-income countries LMICs where access to timely diagnosis and treatment is often limited. This prospective, multicenter observational study follows CAYAs with cancer receiving routine care at participating hospitals in LMICs, aiming to better understand treatment outcomes and challenges faced by patients and families. Participants receive standard medical care as provided by their local hospitals without experimental treatments or changes to their treatment plans. The study observes a single group of patients over time to collect information from medical records and questionnaires focusing on access to care and social factors impacting treatment. The study covers a follow-up period extending up to 36 months after enrollment. During the study, researchers will gather data on clinical outcomes, treatment complications, interruptions, and social factors affecting care. Data collection includes medical record reviews and patient or family questionnaires. The study aims to provide valuable information to help improve cancer care and outcomes in resource-limited settings, with total participant engagement lasting up to three years.

Age: 0Years - 21YearsAll Genders
6 locations
I

Actively Recruiting

This research aims to evaluate cancer treatment outcomes among children, adolescents, and young adults aged 0 to 21 years living in low- and middle-income countries LMICs. It focuses on acute lymphoblastic leukemia ALL and lymphoblastic lymphoma LBL, conditions where treatment success varies widely between high-income and LMICs due to factors like delayed diagnosis and limited access to quality care. The study seeks to inform future efforts to improve cancer care and reduce treatment failures in these regions. The study involves a retrospective review of medical records from participating oncology centers in countries including Guatemala, Honduras, El Salvador, Armenia, and Tanzania. It includes patients with any type of cancer diagnosis who received substantial anti-cancer treatment such as chemotherapy, surgery, radiation, or immunotherapy. Special attention is given to patients with ALL or LBL to assess therapy-related toxicities and treatment outcomes over a three-year follow-up period. Participants medical records will be analyzed to estimate the incidence of treatment failure, including relapse or progression, and therapy-related severe toxicities. Data on event-free survival and overall survival will also be collected. No experimental treatments are administered, as this is a purely observational study. The study period covers up to three years from each patients cancer diagnosis, using existing health data to better understand treatment challenges and outcomes in LMICs.

Age: 0Years - 21YearsAll Genders
7 locations
C

Actively Recruiting

Researchers are collecting detailed information about patients with venous thromboembolism VTE to improve understanding of this condition, especially in groups often excluded from clinical trials such as pregnant women, elderly patients, and those with severe health issues. This observational registry aims to provide data that can help reduce death rates, recurrences of blood clots, bleeding problems, and arterial events related to VTE. This study gathers clinical details about each patient, including other health conditions, and tracks the type, dose, duration, and results of antithrombotic treatments over the first three months. The registry is accessible online to assist doctors in managing complex cases by comparing patient profiles and identifying those at higher risk of complications. Participants clinical status and treatment outcomes are recorded, focusing on recurrence of VTE, bleeding events, and mortality over a three-year period. The information supports the creation of predictive scores to help healthcare providers identify patients at higher risk. The study started in 2001 and plans to continue until 2027, with ongoing data collection and follow-up.

All AgesAll Genders
305 locations
S

Actively Recruiting

Healthy Volunteer

Researchers are evaluating whether a single intake of 30g of dark chocolate with at least 80% cocoa can improve the reactivity of the fetal non-stress test NST in pregnant women who currently have a non-reactive NST. This single-blind, randomized clinical trial focuses on pregnant women between 36 and 41 weeks gestation with singleton pregnancies. The goal is to see if dark chocolate can increase the rate of NSTs becoming reactive within 20 minutes compared to a sugar-free white chocolate placebo. This study also examines related heart rate patterns and maternal satisfaction. Participants will be randomly assigned to one of two groups one group will consume a single oral dose of 30g dark chocolate within 5 minutes after a baseline non-reactive NST, while the control group will receive a single oral dose of 30g sugar-free white chocolate as a placebo. The study tracks changes in fetal heart activity and time spent in monitoring, along with any maternal side effects. The trial is designed to assess the superiority of dark chocolate over placebo in converting NST status. During the study, participants will undergo a baseline NST followed by treatment intake and monitoring for up to 60 minutes. Researchers will measure the proportion of NSTs that become reactive within 20 minutes, changes in fetal heart rate accelerations and variability, total monitoring time, and the need for further fetal tests or urgent obstetric interventions within 24 hours. Maternal satisfaction and any adverse events will be evaluated shortly after intervention. Participants will be followed up by telephone or electronic device for safety within 24 hours. The trial is planned to last until September 2026.

Age: 18Years - 49YearsFEMALEPhase Not Applicable
1 location
P

Actively Recruiting

Healthy Volunteer

Postoperative pain after cesarean section is a common challenge that can slow recovery, delay walking, and affect newborn care. This trial evaluates the safety and effectiveness of photobiomodulation PBM, a non-invasive light therapy using red and near-infrared light, as an additional treatment to standard pain relief methods in postpartum women undergoing cesarean delivery. The study is randomized, double-blind, and sham-controlled, involving 210 women aged 18 to 40 years. Participants are randomly assigned to one of two groups. One group receives active PBM using the MitoQUAD4 Belt device applied over the surgical wound through a sterile dressing for three 15-minute sessions at 30 minutes, 24 hours, and between 36 to 48 hours after surgery, alongside standard multimodal analgesia. The other group receives a sham device that looks and operates like the active device but delivers no therapeutic light, applied on the same schedule with the same standard pain treatments. During the 48 hours following surgery, participants will be monitored for pain intensity at rest and with movement, use of rescue pain medications, wound healing using the REEDA scale, time to first independent walking, maternal satisfaction with childbirth experience, and any adverse events. The main outcome is pain intensity at rest 24 hours after surgery. Safety and treatment effects will be assessed through questionnaires, clinical evaluations, and adverse event tracking over this period.

Age: 18Years - 45YearsFEMALEPhase Not Applicable
1 location
I

Actively Recruiting

Researchers are investigating the nutritional status and its impact on treatment outcomes in children and adolescents newly diagnosed with B- or T-cell acute lymphoblastic leukemia or mixed phenotype acute leukemia. This observational study aims to create a biobank of clinical data and biological specimens from participants aged 3 to 18 years, enhancing understanding of cancer progression, prognosis, treatment toxicities, survivorship, and late effects, especially in low and middle income countries. Participants will have biological samples such as stool and blood collected at key treatment milestones including diagnosis, end of induction, beginning of maintenance, end of treatment, and one year post-treatment. Alongside, data on socioeconomic status, food security, diet, physical activity, and nutritional measurements like height, weight, and arm size will be gathered throughout the treatment period and follow-up. During the study, researchers will collect demographic, lifestyle, clinical, and nutritional information at various timepoints to accompany the biorepository. The main outcomes include establishing a multinational biobank and compiling comprehensive data on treatment-related toxicities, survival, and nutrition over seven years. Participant involvement includes multiple assessments and sample collections over the treatment course and one year after treatment ends.

Age: 3Years - 18YearsAll Genders
8 locations

1-10 of 18

1